Characteristics and outcomes of people living with HIV hospitalised at tertiary healthcare institutions during the COVID-19 pandemic in Mexico City.
AIDS
Hospitalisation
Latin America
México
Observational
SARS-CoV-2
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
24 May 2024
24 May 2024
Historique:
received:
06
10
2023
accepted:
08
03
2024
medline:
25
5
2024
pubmed:
25
5
2024
entrez:
24
5
2024
Statut:
epublish
Résumé
While existing research on people living with HIV (PWH) during the COVID-19 pandemic primarily focused on their clinical outcomes, a critical gap remains in understanding the implications of COVID-19 delivery of in-hospital care services to PWH. Our study aimed to describe the characteristics and outcomes of PWH hospitalised during 2020 in Mexico City, comparing patients admitted due to COVID-19 vs. patients admitted due to other causes. All PWH hospitalised for ≥ 24 h at four institutions in Mexico City from January 1st to December 31st, 2020 were included. Patients were classified into two groups according to the leading cause of their first hospitalisation: COVID-19 or non-COVID-19. Characteristics among groups were compared using chi-square and Kruskal tests. A Cox model was used to describe the risk of death after hospitalisation and the characteristics associated with this outcome. Mortality and hospitalisation events were compared to data from 2019. Overall, we included 238 PWH hospitalised in 2020. Among them, 42 (18%) were hospitalised due to COVID-19 and 196 (82%) due to non-COVID-19 causes, mainly AIDS-defining events (ADE). PWH hospitalised due to COVID-19 had higher CD4 + cell counts (380 cells/mm3 [IQR: 184-580] vs. 97 cells/mm3 [IQR: 34-272], p < 0.01) and a higher proportion of virologic suppression (VS) compared to those hospitalised due to non-COVID-19 causes (92% vs. 55%, p < 0.01). The adjusted hazard ratio (aHR) for AIDS was 3.1 (95%CI: 1.3-7.2). COVID-19 was not associated with death (aHR 0.9 [95%CI: 0.3-2.9]). Compared to 2019, mortality was significantly higher in 2020 (19% vs. 9%, p < 0.01), while hospitalisations decreased by 57%. PWH with COVID-19 had higher VS and CD4 + cell counts and lower mortality compared to those hospitalised due to non-COVID-19-related causes, who more often were recently diagnosed with HIV and had ADEs. Most hospitalisations and deaths in 2020 in PWH were related to advanced HIV disease. The increased mortality and decreased hospitalisations of PWH during 2020 evidence the impact of the interruption of health services delivery for PWH with advanced disease due to the pandemic. Our findings highlight the challenges faced by PWH during 2020 in a country where advanced HIV remains a concern.
Sections du résumé
BACKGROUND
BACKGROUND
While existing research on people living with HIV (PWH) during the COVID-19 pandemic primarily focused on their clinical outcomes, a critical gap remains in understanding the implications of COVID-19 delivery of in-hospital care services to PWH. Our study aimed to describe the characteristics and outcomes of PWH hospitalised during 2020 in Mexico City, comparing patients admitted due to COVID-19 vs. patients admitted due to other causes.
METHODS
METHODS
All PWH hospitalised for ≥ 24 h at four institutions in Mexico City from January 1st to December 31st, 2020 were included. Patients were classified into two groups according to the leading cause of their first hospitalisation: COVID-19 or non-COVID-19. Characteristics among groups were compared using chi-square and Kruskal tests. A Cox model was used to describe the risk of death after hospitalisation and the characteristics associated with this outcome. Mortality and hospitalisation events were compared to data from 2019.
RESULTS
RESULTS
Overall, we included 238 PWH hospitalised in 2020. Among them, 42 (18%) were hospitalised due to COVID-19 and 196 (82%) due to non-COVID-19 causes, mainly AIDS-defining events (ADE). PWH hospitalised due to COVID-19 had higher CD4 + cell counts (380 cells/mm3 [IQR: 184-580] vs. 97 cells/mm3 [IQR: 34-272], p < 0.01) and a higher proportion of virologic suppression (VS) compared to those hospitalised due to non-COVID-19 causes (92% vs. 55%, p < 0.01). The adjusted hazard ratio (aHR) for AIDS was 3.1 (95%CI: 1.3-7.2). COVID-19 was not associated with death (aHR 0.9 [95%CI: 0.3-2.9]). Compared to 2019, mortality was significantly higher in 2020 (19% vs. 9%, p < 0.01), while hospitalisations decreased by 57%.
CONCLUSIONS
CONCLUSIONS
PWH with COVID-19 had higher VS and CD4 + cell counts and lower mortality compared to those hospitalised due to non-COVID-19-related causes, who more often were recently diagnosed with HIV and had ADEs. Most hospitalisations and deaths in 2020 in PWH were related to advanced HIV disease. The increased mortality and decreased hospitalisations of PWH during 2020 evidence the impact of the interruption of health services delivery for PWH with advanced disease due to the pandemic. Our findings highlight the challenges faced by PWH during 2020 in a country where advanced HIV remains a concern.
Identifiants
pubmed: 38789972
doi: 10.1186/s12879-024-09208-0
pii: 10.1186/s12879-024-09208-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
524Informations de copyright
© 2024. The Author(s).
Références
Number of COVID-19 deaths reported to WHO (cumulative total) Americas. World Health Organization 2023 data.who.int, WHO Coronavirus (COVID-19) dashboard > Deaths [Dashboard]. https://data.who.int/dashboards/covid19/deaths . Accessed 19 Feb 2024.
INSP. Tablero analítico de seguimiento de casos documentados de SARS-CoV-2 en México. 2023: 1–5. Available from: https://www.insp.mx/informacion-institucional-covid-19.html . Accessed 28 Jun 2023.
Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C et al. Characterizing long COVID: a living systematic review. BMJ Glob Heal. 2021; 6:e005427. Available from: https://gh.bmj.com/lookup/doi/ https://doi.org/10.1136/bmjgh-2021-005427 .
Kiss P, Carcel C, Hockham C, Peters SAE. The impact of the COVID-19 pandemic on the care and management of patients with acute cardiovascular disease: a systematic review. Eur Hear J - Qual Care Clin Outcomes. 2021;7:18–27.
doi: 10.1093/ehjqcco/qcaa084
Seidu S, Hambling C, Holmes P, Fernando K, Campbell NS, Davies S et al. The impact of the COVID pandemic on primary care diabetes services in the UK: A cross-sectional national survey of views of health professionals delivering diabetes care. Prim Care Diabetes. 2022; 16: 257–263, https://doi.org/10.1016/j.pcd.2021.12.015 .
Konstantinoudis G, Cameletti M, Gómez-Rubio V, Gómez IL, Pirani M, Baio G et al. Regional excess mortality during the 2020 COVID-19 pandemic in five European countries. Nat Commun. 2022; 13:482. Available from: https://www.nature.com/articles/s41467-022-28157-3 .
de Lazzari E, Martínez-Mimbrero A, Chivite I, González-Cordón A, Mosquera MM, Laguno M et al. Impact of COVID-19 epidemics on prevention and care for HIV and other sexually transmitted infections. AIDS. 2022; Publish Ah. Available from: https://journals.lww.com/ https://doi.org/10.1097/QAD.0000000000003164 .
Tamargo JA, Martin HR, Diaz-Martinez J, Trepka MJ, Delgado-Enciso I, Johnson A et al. COVID-19 Testing and the impact of the pandemic on the Miami adult studies on HIV cohort. JAIDS J Acquir Immune Defic Syndr. 2021; 87:1016–1023. Available from: https://journals.lww.com/ https://doi.org/10.1097/QAI.0000000000002680 .
Quiros-Roldan E, Magro P, Carriero C, Chiesa A, El Hamad I, Tratta E et al. Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living with HIV followed in a single centre of Northern Italy. AIDS Res Ther. 2020; 17:59. https://doi.org/10.1186/s12981-020-00314-y .
Hensley KS, Jordans CCE, van Kampen JJA, Mollema FPN, Gisolf EH, El Moussaoui R et al. Significant impact of coronavirus disease 2019 (COVID-19) on human immunodeficiency virus (HIV) care in hospitals affecting the first pillar of the HIV care continuum. Clin Infect Dis. 2022; 74:521–524. Available from: https://academic.oup.com/cid/article/74/3/521/6276393 .
Gobierno de la Ciudad de México. Informe de Acciones preventivas en la Contingencia Sanitaria por SARS-CoV‐2 en 2020. 2020. Available from: https://www.google.com/search?client=firefox-be&q=Respuesta+Epidemiol%C3%B3gica+al+VIH+Sida+y+al%0BVirus+de+la+Hepatitis+C+%0Ben+la+Ciudad+de+M%C3%A9xico%0B2020%2C+Clinica+Especializada+Condesa . Accessed 15 May 2023.
2020 UNAIDS, Global AIDS, Update. 2020. Available from: https://www.unaids.org/en/resources/documents/2020/global-aids-report . Accessed 15 May 2023.
Jewell BL, Mudimu E, Stover J, Ten Brink D, Phillips AN, Smith JA et al. Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. Lancet HIV. 2020; 7:e629–e640. https://doi.org/10.1016/S2352-3018(20)30211-3 .
Azamar-Alonso A, Bautista-Arredondo SA, Smaill F, Mbuagbaw L, Costa AP, Tarride JE. Patient characteristics and determinants of CD4 at diagnosis of HIV in Mexico from 2008 to 2017: a 10-year population-based study. AIDS Res Ther. 2021; 18:1–9. https://doi.org/10.1186/s12981-021-00409-0 .
Gobierno de México: Secretaría de Salud. Lineamiento de Reconversión Hospitalaria. Lineamiento reconversión Hosp. 2020; 1:1–27. Available from: https://coronavirus.gob.mx/wp-content/uploads/2020/04/Documentos-Lineamientos-Reconversion-Hospitalaria.pdf . Accessed 3 Apr 2023.
World Health Organization (WHO). Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalised with suspected or confirmed SARS-CoV-2 infection. 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-HIV-2021.1 .
Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, Rebick G, Klein E et al. Outcomes among HIV-positive patients hospitalised with COVID-19. JAIDS J Acquir Immune Defic Syndr. 2020; 85:6–10. Available from: https://journals.lww.com/ https://doi.org/10.1097/QAI.0000000000002423 .
Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021; 8:e24–e32. https://doi.org/10.1016/S2352-3018(20)30305-2 .
Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state. JAMA Netw Open. 2021; 4:e2037069. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775827 .
Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, Villa G, et al. Outcomes of coronavirus disease 2019 (COVID-19) related hospitalisation among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) clinical characterization protocol (UK): a prospective observational study. Clin Infect Dis. 2021;73:e2095–106.
doi: 10.1093/cid/ciaa1605
pubmed: 33095853
Kamis KF, Barbera L, Abdo M, Rowan SE, Hussain C, Gardner EM et al. Risk factors for hospitalisation in people with HIV and COVID-19. JAIDS J Acquir Immune Defic Syndr. 2021; 88:e22–e22. 10.1097/QAI.0000000000002780, Available from: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinte.159.17.2053 .
Bell N, Bracchi M, Dalla Pria A, Nelson M, Boffito M. Indirect human immunodeficiency virus morbidity and mortality due to coronavirus disease 2019. Clin Infect Dis. 2021; 73 (10):1947–1949. https://doi.org/10.1093/cid/ciab128 Available from: https://academic.oup.com/cid/article/73/10/1946/6076528 .
Secretaria de Salud CENSIDA. 2021. Guía de manejo antiretroviral de las personas con VIH en México. Available from: https://www.gob.mx/censida/documentos/guia-de-manejo-antirretroviral-de-las-personas-con-vih-mexico-2021-297710 .
Kwee TC, Kwee RM. Chest CT in COVID-19: What the radiologist needs to know. RadioGraphics. 2020; 40:1848–1865. Available from: http://pubs.rsna.org/doi/10.1148/rg.2020200159 .
Guía Clínica para el Tratamiento de la COVID19 en México. Consenso Interinstitucional. Actualización: 2 de agosto de 2021. Secretaria de Salud, México 2021. Available from: https://coronavirus.gob.mx/wp-content/uploads/2021/08/GuiaTx_COVID19_ConsensoInterinstitucional_2021.08.03.pdf .
Sistema de Vigilancia Epidemiológica de VIH. Informe Histórico al 4to Trimestre de VIH 2020. Dirección de Vigilancia Epidemiológica de Enfermedades Transmisibles. Secretaria de Salud, México 2020. Available from: https://www.gob.mx/cms/uploads/attachment/file/622468/VIH-Sida_4toTrim_2020 pdf.
WHO. 2021. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalised with suspected or confirmed SARS-CoV-2 infection. https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-HIV-2021.1 .
Gatechompol S, Avihingsanon A, Putcharoen O, Ruxrungtham K, Kuritzkes DR. COVID-19 and HIV infection co-pandemics and their impact: a review of the literature. AIDS Res Ther. 2021; 18:28. https://doi.org/10.1186/s12981-021-00335-1 .
Vizcarra P, Pérez-Elías MJ, Quereda C, Moreno A, Vivancos MJ, Dronda F et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020; 7:e554–e564. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2352301820301648 .
Volkow P, Lárraga-Mancilla V, Mendoza MJ, Cornejo-Juárez P, Islas-Muñoz B, Pérez-Jiménez C, et al. Impact of COVID-19 pandemic in the care of people living with HIV and cancer at an oncologic center in Mexico. Int J STD AIDS. 2023 Mar;34(3):159-167. Available from: https://pubmed.ncbi.nlm.nih.gov/36527188/
doi: 10.1177/09564624221142364
pubmed: 36527188
Macías-Gonzáles F, Vermandere H, Piñeirúa-Menendez A, Bautista-Arredondo S. How the COVID-19 pandemic and the Health System’s response reduced HIV testing and increased late diagnoses in Mexico. AIDS. 2024. https://doi.org/10.1097/QAD.0000000000003833 .
doi: 10.1097/QAD.0000000000003833
Núñez I, Amuchastegui A, Vásquez-Salinas A, Díaz S, Caro-Vega Y. Challenges to the HIV Care Continuum During the COVID-19 Pandemic in Mexico: A Mixed Methods Study. AIDS Behav. 2023 Oct 4. https://doi.org/10.1007/s10461-023-04195-w . Epub ahead of print. PMID: 37789236.
Gutiérrez-Velilla E, Piñeirúa-Menéndez A, Ávila-Ríos S, Caballero-Suarez N. Clinical follow-up in people living with HIV during the COVID-19 pandemic in Mexico. AIDS Behav. 2022, 26, 2798–2812. https://doi.org/10.1007/s10461-022-03626-4 .
Nomah DK, Reyes-Urueña J, Llibre JM, Ambrosioni J, Ganem FS, Miró JM, Casabona J. HIV and SARS-CoV-2 co-infection: epidemiological, clinical features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-risk groups. Curr HIV/AIDS Rep. 2022;19(1):17–25. https://doi.org/10.1007/s11904-021-00596-5 .
doi: 10.1007/s11904-021-00596-5
pubmed: 35113346
pmcid: 8810339
SeyedAlinaghi S, Mirzapour P, Pashaei Z, Afzalian A, Tantuoyir MM, Salmani R, et al. The impacts of COVID-19 pandemic on service delivery and treatment outcomes in people living with HIV: a systematic review. AIDS Res Therapy. 2023;20(1):4. https://doi.org/10.1186/s12981-022-00496-7 .
doi: 10.1186/s12981-022-00496-7
Waters LJ, Pozniak AL. COVID-19 death in people with HIV: interpret cautiously. Lancet HIV. 2021; 8:e2–e3. https://doi.org/10.1016/S2352-3018(20)30332-5 .
Zang X, Krebs E, Chen S, Piske M, Armstrong WS, Behrends, et al. Localized HIV modeling study. The potential epidemiological impact of Coronavirus Disease 2019 (COVID-19) on the human immunodeficiency virus (HIV) Epidemic and the cost-effectiveness of linked, opt-out HIV Testing: a modeling study in 6 US cities. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2021;72(11):e828–34. https://doi.org/10.1093/cid/ciaa1547 .
doi: 10.1093/cid/ciaa1547
Stanford KA, McNulty MC, Schmitt JR, Eller DS, Ridgway JP, Beavis, et al. Incorporating HIV screening with COVID-19 testing in an urban Emergency Department during the pandemic. JAMA Intern Med. 2021;181(7):1001–3. https://doi.org/10.1001/jamainternmed.2021.0839 .
doi: 10.1001/jamainternmed.2021.0839
pubmed: 33843944
pmcid: 8042563
McNulty MC, Stanford KA, Eller D, Sha BE, Purim-Shem-Tov Y, Kishen et al. Concurrent Testing for COVID-19 and HIV Infection at 6 High-Volume Emergency Departments in a Priority Jurisdiction for Ending the HIV Epidemic in the United States. Journal of acquired immune deficiency syndromes 2023, 12 01; 94(4):364–370. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609715/pdf/qai-94-364.pdf .
Brazier E, Ajeh R, Maruri F, Musick B, Freeman A, Wester CW et al. Service delivery challenges in HIV care during the first year of the COVID-19 pandemic: results from a site assessment survey across the global IeDEA consortium. J Int AIDS Soc. 2022, 25: e26036. https://doi.org/10.1002/jia2.26036 .
Quiros-Roldan E, Izzo I, Carriero C, Degli Antoni M, Storti S, Tiecco G, et al. Decrease in new diagnosis of HIV/AIDS in the two years period 2019–2020: impact of COVID-19 pandemic. J Public Health Res. 2021;11(1):2256. https://doi.org/10.4081/jphr.2021.2256 .
doi: 10.4081/jphr.2021.2256
pubmed: 34558252
pmcid: 8883525
Rick F, Odoke W, van den Hombergh J, Benzaken AS, Avelino-Silva VI. Impact of coronavirus disease (COVID-19) on HIV testing and care provision across four continents. HIV Med. 2022;23(2):169–77. https://doi.org/10.1111/hiv.13180 . Epub 2021 Oct 10. PMID: 34632685; PMCID: PMC8653012.
doi: 10.1111/hiv.13180
pubmed: 34632685